|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy.
|
28399576 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The polymorphism rs4430796 of the chromosome 17q12 appears to be a biomarker for cancer aggressiveness, increased PSA and tumor volume of PCa.
|
24627192 |
2014 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to explore perceptions about prostate cancer risk and subsequent opportunistic screening among patients who were not at increased risk of prostate cancer after a first PSA test plus a genetic lifetime risk assessment.
|
29454309 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Guidelines for PSA screening in subgroups with increased risk of prostate cancer diagnosis due to race or genotype are underdeveloped.
|
27742670 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings confirm an increased cancer risk associated with the G84E mutation in the Finnish population, particularly for early-onset prostate cancer and cases with substantially elevated PSA.
|
23292082 |
2013 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that rs4962416, previously associated only with prostate cancer, is also associated with PSA levels, with 12% increase for each copy of the minor allele C. The study enabled the replication of the effect for the majority of previously reported genetic variants in a set of clinically relevant prostate cancers.
|
26773531 |
2016 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genotype TG on 11q13 (rs7931342, T) could be related to an increased Gleason score, AG on HNF1B (rs4430796, A) could be associated with PSA increase, and TG on 17q24 (rs1859962, G) could be negatively associated with an increased BMI in Chinese men with PCa.
|
23464444 |
2012 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In tissue samples, SPRY1 expression levels were significantly lower in prostate cancer patients with PSA recurrence after surgical treatment (P = 0.0076) and JAG1 expression levels were significantly higher in Gleason sum (GS) 8-9 disease than in GS 5-6 (P = 0.0121).
|
24604720 |
2014 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Logistic analyses of the DKK3 gene polymorphisms with several prostate cancer related factors showed that several SNPs were significant; three SNPs and two haplotypes to PSA level, three SNPs and two haplotypes to clinical stage, nine SNPs and two haplotype to pathological stage, one SNP and one haplotypes to Gleason score.
|
26689513 |
2016 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.
|
26068399 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In secondary analyses, the model predicted the endpoints of prostate cancer death (in SYS cases) and systemic progression beyond 5 years (in PSA controls) with hazard ratios 2.5 and 4.7, respectively (log-rank p-values of 0.0007 and 0.0005).
|
18846227 |
2008 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Study Finds Overall Prostate Cancer Mortality Decreases with PSA Screening.
|
29189229 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sub-group analyses focused on those men with low-risk PCa (T1-2a, PSA ≤10 ng/mL, Gleason ≤6).
|
28534659 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although, more clinical validations are needed for the stratification of PC risk in ASAP-diagnosed biopsy cores, our current results indicate that the coexistence of T2E fusion positivity with MMP-2 upregulation may help clinicians adjust their biopsy timetable and/or assessment of PC risk in ASAP-diagnosed patients with a PSA level of 4-10 ng/mL.
|
30294801 |
2019 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analyses were restricted to 2007 patients who harbored low-risk PCa at ≥10-cores initial biopsy according to D'Amico classification (PSA <10.0 ng/ml, Gleason score <7 and clinical stage ≤T2a).
|
27289238 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The original ERSPC risk calculator 3 (RC3) for prostate cancer (PCa) and high-grade PCa (HGPCa) was applied to a development cohort of 3006 previously unscreened Hong Kong Chinese men with initial transrectal biopsies performed from 1997 to 2015, age 50-80 years, PSA 0.4-50 ng ml<sup>-1</sup> and prostate volume 10-150 ml.
|
27897172 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In our study, it appears that there may be an association between the number of sexual partners and prostate cancer in the patient group with PSA level above 4ng/mL.
|
29570262 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined Early and Late [<sup>68</sup>Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.
|
30105521 |
2019 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PSA(G/G) genotype (OR = 1.78, 95% CI = 1.06–2.99) and AR short CAG repeats (OR = 1.89, 95% CI = 1.21–2.96) increased risk for prostate cancer and were related with tumor aggressiveness.
|
20632874 |
2010 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We therefore studied VDR gene polymorphisms, as detected by Apal and Taql restriction fragments, in multiethnic Brazilian men (165 patients and 200 controls) for association with prostate cancer risk and parameters of disease severity (serum PSA, Gleason score and tumor stage).No statistical correlations were found.
|
15503828 |
2005 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between rs6983267 and risk of PCa under different clinical conditions, further analyses were conducted regarding different clinical characteristics including the Gleason score, tumor stage, and PSA level to provide a more comprehensive view of PCa risk and this SNP.
|
26782586 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 101 consecutive patients suspicious of prostate cancer (PCa) at the mpMRI scan and with prior negative biopsy and elevated PSA values were prospectively recruited at two urological centers.
|
28679370 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'.
|
29248950 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.
|
25750310 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Improvements in PSA outcomes for high-risk PCa using IG-IMRT vs. IMRT without IG may be due to improved dosimetry for ECD.
|
29650035 |
2018 |